Technology Development Recent Happenings

Inventors Recognition Program

United States Patent 9,968,693 was issued on May 15, 2018 for Small molecule imaging of fungi by positron emission tomography scanning. NIAID inventors: Dr Peter Richard Williamson, Dr Dale KiesewetterDr Jin Qui

United States patent 9,890,369 was issued on February 13, 2018 for Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor. Dr Steve Leppla 

United States patent 9,957,486 was issued on May 1, 2018 for Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization. NIAID inventors: Dr Peter L CollinsDr Ursula J. Buchholz, Dr Cyril Le Nouen

United States patent 10,000,556 was issued on June19, 2018 for Single-domain V.sub.HH antibodies directed to norovirus GI.1 and GII.4 and their use.  NIAID inventors: Dr Karin Bok, Dr Lisbeth Kim Green, Stanislav Sosnovtsev 

Recent Patents

United States Patent 9,884,100 was issued on February 6, 2018 for Lutzomyia longipalpis polypeptides and methods of use. NIAID Inventors: Jesus G. Valenzuela, Ph.D., Jose Ribeiro M. C.,

United States Patent 9,974,796 was issued on May 22, 2018 for Inhibitors of the plasmodial surface anion channel as antimalarials. NIAID inventors: Dr. Sanjay Desai

United States Patent 10,017,543 was issued on July 10, 2018 for Prefusion RSV F proteins and their use.  NIAID Inventors:  Peter Kwong PhDBarney S. Graham, PhD; Dr. Gwo-Yu Chuan; Jason Gorman, Marie Pancera; Mallika Sastry, Guillaume Stewart-Jones; Baoshan Zhang, PhD; Tongqing Zhou, PhD

United States Patent 10,035,844 was issued on July 31, 2018  for  Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein. NIAID inventors: Peter Kwong PhD; John R. Mascola, PhD; Dr. Mark Connors

United States Patent 10,047,147 was issued on August 14, 2018 for Neutralizing GP41 antibodies and their use. NIAID inventors: Dr. Mark Connors; John R. Mascola, PhD; Nicole Amy Doria-Rose, PhD

United States Patent 10,047,148 was issued on August 14, 2018 for Neutralizing GP41 antibodies and their use.  NIAID inventors: Dr. Mark Connors; Peter Kwong PhD; John R. Mascola, PhD; Baoshan Zhang, PhD;

United States Patent 10,053,503 was issued on August 21, 2018 for Monoclonal antibodies that neutralize anthrax toxins. NIAID Inventors: Zhaochun Chen PhD; Stephen H. Leppla, PhD;  Ms. Mahtab Moayeri

United States Patent 10,058,559 was issued on August 21, 2018 for Treatment or prevention of an intestinal disease or disorder  NIAID inventors: Dr. Warren Strober; Mr. Ivan J. Fuss,  Atsushi Kitani, MD, PhD.

United States Patent 10,058,602 was issued on August 28, 2018 for Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus. NIAID inventors: Alexander G. Pletnev, PhD; Stephen S. Whitehead, PhD; Joseph E. Blaney, PhD, MBA

Recent Collaborative Agreements

NIAID and Kephera Diagnostics, LLC. signed a human research collaboration agreement (hu-RCA) Development of a point-of-care test for Lyme disease that can be performed at the site of patient care to help clinicians to evaluate patients and improve care. NIAID principle investigator: Dr. Adriana Marques

NIAID and University of Glasgow signed a standard research collaboration agreement (RCA-S) to study the sequestration pattern of early/immature gametocyte stages in the bone marrow using Non-Human Primate (NHP) models. NIAID principle investigator: Dr. Thomas E. Wellems

NIAID and University of Washington signed a human research collaboration agreement (hu RCA) to evaluate virus-specific T cell responses in samples from patients presenting with severe or unusual viral infections. NIAID principle investigator: Dr. Jeffrey Cohen, MD

NIAID and Lumen Bioscience Inc. signed Use of Lumen Bioscience's protein expression technology with NIAID/VRC's influenza and HIV immunogens.  NIAID principle investigator: Dr. Barney Graham

NIAID and New York University School of Medicine (NYU) signed a human research collaboration agreement (Hu-RCA) to characterize the peanut allergic patients for their anaphylaxis risk and carry out the first characterization of IgE serum antibodies from isolated patients’ blood. NIAID principle investigator: Dr. Jeffrey Cohen, MD

NIAID and Lumen Bioscience Inc. signed a standard research collaboration agreement (RCA-S) for the use of protein expression technology with NIAID/VRC's influenza and HIV immunogens.  NIAID principle investigator: Dr. Barney Graham

NIAID and Scripps Research Institute (TSRI) signed a standard research collaboration agreement (RCA-S) to develop a universal influenza vaccine through characterization of neutralizing antibody-hemagglutinin structure.   NIAID principle investigator: Adrian Bernard McDermott  

NIAID and Duke University signed a human research collaboration agreement (Hu-RCA) on the effect of alpha globin on nitric oxide regulation in both asthma and vascular disease. NIAID principle investigators: Dr. Hans C. AckkermanDr. Parker Amy Ruhl, MD , Loretta Qu

NIAID and US Army Medical Research Institute of Infectious Diseases (USAMRIID) (DoD) signed a standard research collaboration agreement (RCA-S) to recreate (“rescue”) Ebola virus variant (EBOV) using plasmids encoding the EBOV genome.  NIAID principle investigator: Dr. Peter Jahrling 

NIAID and Cogen Therapeutics, Inc. signed a standard research collaboration agreement (RCA-S) to use antibody and antigen labeling techniques to image, detect, count, and sort cells according to their antigen specificity. NIAID principle investigator: Dr.Daniel Douek

NIAID and University of Oxford signed a standard research collaboration agreement (RCA-S) to design and test its adeno virus and VRC's peptide adjuvant nanoparticle vaccine. NIAID principle investigator: Dr. Robert Seder

NIAID and Avatar Medical, LLC signed a standard research collaboration agreement (RCA-S) to collaborate to develop reagents that will facilitate the development of RSV vaccine assays. NIAID principle investigator: Barney Graham, MD, PhD

NIAID and MockV Solutions signed a standard research collaboration agreement (RCA-S) for VPP to evaluate MockV's technology that is designed to reduce costs and technical hurdles for advancing experimental vaccines into clinical trials. NIAID principle investigator: Daniel Gowetski, PhD

Content last reviewed on October 11, 2018